NCT06522386View on ClinicalTrials.gov

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2029

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Pirtobrutinib

Given by mouth

DRUG

Rituximab

Given by vein (IV)

DRUG

Venetoclax

Given by mouth

Trial Locations (2)

55902

RECRUITING

Mayo Clinic in Rochester, Rochester

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (2)

Genentech, Inc.
AbbVie
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

collaborator

AbbVie

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER